WO2022018884A1 - 栄養障害型表皮水疱症の治療薬 - Google Patents
栄養障害型表皮水疱症の治療薬 Download PDFInfo
- Publication number
- WO2022018884A1 WO2022018884A1 PCT/JP2020/044096 JP2020044096W WO2022018884A1 WO 2022018884 A1 WO2022018884 A1 WO 2022018884A1 JP 2020044096 W JP2020044096 W JP 2020044096W WO 2022018884 A1 WO2022018884 A1 WO 2022018884A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- ability
- acid sequence
- blister
- derived
- Prior art date
Links
- 208000010975 Dystrophic epidermolysis bullosa Diseases 0.000 title claims abstract description 36
- 208000004298 epidermolysis bullosa dystrophica Diseases 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 title description 5
- 229940124597 therapeutic agent Drugs 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 53
- 108010017377 Collagen Type VII Proteins 0.000 claims abstract description 51
- 102000004510 Collagen Type VII Human genes 0.000 claims abstract description 50
- 210000004027 cell Anatomy 0.000 claims description 280
- 101150056204 COL7A1 gene Proteins 0.000 claims description 56
- 101100496573 Homo sapiens COL7A1 gene Proteins 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 43
- 150000007523 nucleic acids Chemical group 0.000 claims description 39
- 230000004069 differentiation Effects 0.000 claims description 37
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 36
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 34
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 33
- 210000001185 bone marrow Anatomy 0.000 claims description 26
- 239000007790 solid phase Substances 0.000 claims description 17
- 210000001789 adipocyte Anatomy 0.000 claims description 16
- 210000000963 osteoblast Anatomy 0.000 claims description 16
- 210000001612 chondrocyte Anatomy 0.000 claims description 15
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
- 208000002720 Malnutrition Diseases 0.000 claims description 13
- 102100037241 Endoglin Human genes 0.000 claims description 10
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 10
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 10
- 230000001771 impaired effect Effects 0.000 claims description 10
- 230000001071 malnutrition Effects 0.000 claims description 10
- 235000000824 malnutrition Nutrition 0.000 claims description 10
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 9
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 9
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 9
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 9
- 239000000853 adhesive Substances 0.000 claims description 9
- 230000001070 adhesive effect Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims description 8
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 8
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 8
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 8
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims description 8
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 8
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 8
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 8
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 8
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000002352 blister Diseases 0.000 abstract description 4
- 241000197194 Bulla Species 0.000 abstract 1
- 239000013598 vector Substances 0.000 description 50
- 239000002609 medium Substances 0.000 description 27
- 239000013603 viral vector Substances 0.000 description 23
- 108091033409 CRISPR Proteins 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 21
- 108020005004 Guide RNA Proteins 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 15
- 238000010186 staining Methods 0.000 description 15
- 108010042407 Endonucleases Proteins 0.000 description 14
- 238000010362 genome editing Methods 0.000 description 14
- 230000035772 mutation Effects 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 12
- 238000004806 packaging method and process Methods 0.000 description 11
- 102100031780 Endonuclease Human genes 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000002469 basement membrane Anatomy 0.000 description 10
- 238000010354 CRISPR gene editing Methods 0.000 description 9
- 210000004207 dermis Anatomy 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 108010061833 Integrases Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000012239 gene modification Methods 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 101000909498 Homo sapiens Collagen alpha-1(VII) chain Proteins 0.000 description 7
- 102100034343 Integrase Human genes 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 108091027544 Subgenomic mRNA Proteins 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 102100024335 Collagen alpha-1(VII) chain Human genes 0.000 description 5
- 241000702421 Dependoparvovirus Species 0.000 description 5
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
- 238000004873 anchoring Methods 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000005017 genetic modification Effects 0.000 description 4
- 235000013617 genetically modified food Nutrition 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108091079001 CRISPR RNA Proteins 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 108091028113 Trans-activating crRNA Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 102220032988 rs281865408 Human genes 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 108700001624 vesicular stomatitis virus G Proteins 0.000 description 3
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 2
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000028782 Hereditary disease Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000024556 Mendelian disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 241000713325 Visna/maedi virus Species 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052754 neon Inorganic materials 0.000 description 2
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 241000093740 Acidaminococcus sp. Species 0.000 description 1
- 241000486679 Antitype Species 0.000 description 1
- 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 1
- 108700004991 Cas12a Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 101500026551 Homo sapiens Transforming growth factor beta-3 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- 241000689670 Lachnospiraceae bacterium ND2006 Species 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000019748 bullous skin disease Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000009816 chondrogenic differentiation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 208000008106 junctional epidermolysis bullosa Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000037436 splice-site mutation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present disclosure relates to a therapeutic agent for nutritionally impaired epidermolysis bullosa.
- Epidermolysis bullosa is a disease in which the epidermis peels off from the dermis and causes blisters (blisters) and skin ulcers when force is applied to the skin due to the loss or disappearance of the adhesive structural molecules responsible for the adhesion of skin tissue. be.
- the type in which the epidermis is torn and blisters are formed is simple epidermolysis bullosa
- the type in which blisters are formed by peeling between the epidermis and the dermis is junctional epidermolysis bullosa, and the part between the epidermis and the dermis is peeled off.
- the type of disease is called epidermolysis bullosa.
- Nutritional disorder type epidermolysis bullosa is the most common type of epidermolysis bullosa, accounting for about 50% of all epidermolysis bullosa, and is a hereditary disease caused by a mutation in the COL7A1 gene that encodes type VII collagen.
- the epidermal basal cells at the bottom of the epidermis are bound to a sheet-like structure called the basement membrane.
- Type VII collagen forms a fiber called anchoring fibril in the dermis and connects the basement membrane and the dermis.
- Skin sheets are difficult to manufacture because they require advanced process control and culture technology, and are expensive, so there is a demand for therapeutic agents that are easier to manufacture.
- the present disclosure is a composition for use in the treatment of dystrophic epidermolysis bullosa, comprising blistering-derived cells of a dystrophic epidermolysis bullosa patient genetically modified to produce type VII collagen. Regarding the composition.
- the present disclosure provides a therapeutic agent for nutritionally impaired epidermolysis bullosa.
- FIG. 1 is a photograph showing the appearance of blister-derived cells up to 20 days after the start of culture.
- FIG. 2 shows the results of FACS analysis of blister-derived cells and human bone marrow-derived mesenchymal stem cells (BM-MSC).
- BM-MSC bone marrow-derived mesenchymal stem cells
- FIG. 3 blisters-derived cells and human BM-MSC are cultured under conditions for inducing differentiation into osteoblasts, adipocytes, and chondrocytes, and are stained with alkaline phosphatase (ALP), oil red O, and alcian blue, respectively. The result of the above is shown.
- FIG. 4 shows the cleavage of genomic DNA by the designed sgRNA (sgAAVS1- # 1 to # 3) and its cleavage efficiency.
- FIG. 1 is a photograph showing the appearance of blister-derived cells up to 20 days after the start of culture.
- FIG. 2 shows the results of FACS analysis of blister-derived cells and human bone
- FIG. 5 is an explanatory diagram of genome editing in which the COL7A1 gene is introduced into the AAVS1 region.
- HA-R and HA-L indicate the homologous sequence part
- SA indicates the splice acceptor sequence
- T2A indicates the T2A sequence encoding the T2A peptide
- Puro indicates the puromycin resistance gene
- CAG indicates the CAG promoter sequence.
- the length from F2 to R2 in the wild-type genome (top) is 1952 bp
- the length from F1 to R1 in the genome into which the COL7A1 gene is introduced (bottom) is 1246 bp
- the length from F2 to R2 is 14249 bp. be.
- FIG. 6 is an explanatory diagram of the production of an epidermolysis bullosa model mouse.
- the photo on the right shows the formed blisters.
- FIG. 7 shows a skin tomographic image of an epidermolysis bullosa model mouse in which blister-derived cells are injected into the blister.
- the photo on the left shows the results of immunostaining for type VII collagen
- the photo on the right shows the results of immunostaining for DAPI staining and type VII collagen.
- Control shows the results of mice injected with unmodified blister-derived cells
- CAG-hCOL7 shows the results of mice injected with COL7A1 gene-introduced blister-derived cells.
- Dystrophic Epidermolysis Bullosa is a hereditary disease caused by a mutation in the COL7A1 gene that encodes type VII collagen, and type VII collagen is not produced at all or its function is impaired by the mutation. It is known that type VII collagen is produced as its characteristic. Type VII collagen forms a fiber called anchoring fibril in the dermis and connects the basement membrane and the dermis. Type VII collagen contains a first non-collagen region, a collagen region, and a second non-collagen region from the N-terminal, and forms a triple chain at the collagen region portion characterized by a repeating sequence of glycine-XY, forming a triple chain and a C-terminal.
- Mutations include mutations in which glycine in the collagen region is replaced with other amino acids, stop codon mutations that stop protein translation, and splice site mutations.
- the mutation may be in one of the alleles or in both.
- the malnourished epidermolysis bullosa includes a dominant malnutrition type and a recessive malnutrition type, and the recessive malnutrition type includes a severe generalized type and other generalized types with relatively mild symptoms.
- the malnutrition-type epidermolysis bullosa in the present specification may be any type of malnutrition-type epidermolysis bullosa, and may be caused by a mutation in any COL7A1 gene.
- the blister-derived cells of a dystrophic epidermolysis bullosa patient refer to adherent cells collected from within the blister of a dystrophic epidermolysis bullosa patient, and in the present disclosure, "DEB patient blister-derived cells” or Also called “blister-derived cells”.
- the cells can be obtained by culturing the blister contents of a nutritionally impaired epidermolysis bullosa patient on a solid phase.
- the blister contents can be collected from the blisters of a nutritionally impaired epidermolysis bullosa patient by means such as a syringe.
- the solid phase means a solid support to which cells can adhere, and includes, for example, a culture vessel made of plastic or glass, such as a culture dish, a flask, or a multi-well plate.
- the solid phase is a plastic culture vessel.
- the solid phase may be coated, and examples of the coating substance include collagen I, laminin, vitronectin, fibronectin, poly-L-lysine, and poly-L-ornithine.
- the solid phase is coated with collagen I. Culturing can be carried out in a general incubator under conditions such as "37 ° C, 5% CO 2 ", "37 ° C, 5% O 2 , 5% CO 2".
- the culture medium may be any medium that can be used for culturing animal cells, for example, MEM, MEM ⁇ , DMEM, GMEM, RPMI 1640, MesenCult TM (STEMCELL Technologies), Messengerle Stem Cell Growth Medium 2 (PromoCell). , MSCGM Mesenchymal Stem Cell Growth Medium (Lonza), Cellartis MSC Xeno-Free Culture Medium (Takara Bio), and a mixed medium thereof.
- the culture period may be long enough for the cells to adhere to the solid phase, eg, 1 day to several months (eg, 2, 3 or 4 months), 1 day to 1 month, 1 day. It can be from several weeks (eg, two, three or four weeks), one day to one week.
- blister-derived cells of DEB patients have one or more characteristics selected from the following 1) -6): 1) Adhesive to the solid phase, 2) One or more surface markers selected from the group consisting of CD73, CD105 and CD90 are positive. 3) One or more surface markers selected from the group consisting of CD45, CD34, CD11b, CD79A, HLA-DR and CD31 are negative, 4) It does not have the ability to differentiate into osteoblasts, or its differentiation ability is lower than that of bone marrow-derived mesenchymal stem cells. 5) It does not have the ability to differentiate into adipocytes, or its differentiation ability is lower than that of bone marrow-derived mesenchymal stem cells.
- chondrocytes It does not have the ability to differentiate into chondrocytes, or its differentiation ability is lower than that of bone marrow-derived mesenchymal stem cells.
- a cell "does not have the ability to differentiate" into osteoblasts, fat cells or chondrocytes means osteoblasts, fat cells or or using normal differentiation induction conditions and detection methods (staining, etc.). It means that differentiation into cartilage cells cannot be detected.
- the DEB patient blister-derived cells are CD73-positive, CD105-positive, and CD90-positive cells.
- DEB patient blister-derived cells are CD45-negative, CD34-negative, CD11b-negative, CD79A-negative, HLA-DR-negative, and CD31-negative cells.
- DEB patient blisters are cells that are less capable of differentiating into osteoblasts, adipocytes, and chondrocytes than bone marrow-derived mesenchymal stem cells. be.
- DEB patient blisters-derived cells have a lower ability to differentiate into osteoblasts and adipocytes than bone marrow-derived mesenchymal stem cells, and have no ability to differentiate into chondrocytes. It is a cell.
- blister-derived cells of a nutritionally impaired epidermolysis bullosa patient genetically modified to produce type VII collagen are used.
- “cells genetically modified to produce type VII collagen” means cells genetically modified to produce functional (ie, capable of forming anchoring fibrils) type VII collagen.
- the gene modification of a cell means both the modification of a gene in the genome of the cell and the modification of the cell to express the gene from an extragenome nucleic acid construct (for example, a vector). That is, the expression “gene-modify to produce type VII collagen” refers to modifying cells to express type VII collagen from the COL7A1 gene in the genome, and to VII from the COL7A1 gene of the extragenomic nucleic acid construct. It involves modifying cells to express type collagen.
- “cells genetically modified to produce type VII collagen” include cells that express type VII collagen from the COL7A1 gene in the genome and cells that express type VII collagen from the COL7A1 gene, which is a nucleic acid construct outside the genome. And are included.
- Gene modification of cells can be performed by introducing the COL7A1 gene or by modifying the mutation of the COL7A1 gene in the genome.
- the introduction of the COL7A1 gene can be performed either by introducing the COL7A1 gene into the cell genome or by allowing a nucleic acid construct containing the COL7A1 gene to be present in the cell so that the COL7A1 gene is expressed from an extragenome nucleic acid construct. Can be done.
- the COL7A1 gene is introduced into the genome of a cell, it may be introduced at a specific position or may be introduced at random.
- the COL7A1 gene is introduced into the COL7A1 locus of the genome, or a safe harbor such as the AAVS1 region.
- DEB patient blister-derived cells are cells of the dystrophic epidermolysis bullosa patient (ie, autologous cells) to which the cells are administered, but are different from those of the patient receiving the cells. It may be a patient's cell (ie, an allogeneic cell).
- the cells of the epidermolysis bullosa patient with malnutrition include cells that do not produce type VII collagen and cells that produce type VII collagen but whose function is reduced due to mutation.
- the "cells of a patient with epidermolysis bullosa" may be any of them.
- the DEB patient blister-derived cells may be cells that can produce type VII collagen in the vicinity of the epidermal basement membrane when administered to the patient.
- cells are used in the sense of including those grown as needed.
- Cell proliferation can be performed by culturing the cells.
- blister-derived cells in patients with dystrophy-type epidermolysis bullosa
- gene-modified cells are cells obtained by genetic modification. Includes those that have been propagated.
- genetically modified cells may be grown until the amount required for the genetic modification is obtained. Also, after genetic modification, cells may be grown until the amount required for treatment is obtained.
- the term "cell” can mean one cell or a plurality of cells depending on the context. Further, the cell may be a cell population consisting of one type of cell, or may be a cell population including a plurality of types of cells.
- the COL7A1 gene means a nucleic acid sequence encoding type VII collagen, and is used to include cDNA as well as a sequence containing one or more introns (eg, a genomic sequence or a minigene).
- the representative nucleic acid sequence of the human COL7A1 gene (cDNA) is shown in SEQ ID NO: 1, and the representative amino acid sequence of human type VII collagen is shown in SEQ ID NO: 2.
- the cDNA sequence of the COL7A1 gene is disclosed in GenBank: NM_000094.3, and the genomic sequence is disclosed in GenBank: AC121252.4.
- the COL7A1 gene may encode functional type VII collagen (ie, capable of forming anchoring fibrils), and its sequence is not limited.
- CDNA sequence of human COL7A1 gene (8835 bp) (SEQ ID NO: 1) Amino acid sequence of human type VII collagen (2944 AA) (SEQ ID NO: 2) *
- the COL7A1 gene is a nucleic acid having 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or more sequence identity with the nucleic acid sequence of SEQ ID NO: 1. Contains or consists of the nucleic acid sequence. In another embodiment, the COL7A1 gene is 1-30, 1-20, 1-10, 1-5, 1-3, 1-2 or 1 in the nucleic acid sequence of SEQ ID NO: 1. The base contains or consists of the nucleic acid sequence inserted, deleted, substituted, or added. In a further embodiment, the COL7A1 gene comprises or consists of the nucleic acid sequence of SEQ ID NO: 1.
- type VII collagen has 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or more sequence identity with the amino acid sequence of SEQ ID NO: 2. Contains or consists of the amino acid sequence. In another embodiment, type VII collagen is 1-30, 1-20, 1-10, 1-5, 1-3, 1-2 or 1 in the amino acid sequence of SEQ ID NO: 2. Contains or consists of the amino acid sequence of which the amino acid residue of is inserted, deleted, substituted, or added. In a further embodiment, type VII collagen comprises or consists of the amino acid sequence of SEQ ID NO: 2.
- the COL7A1 gene is an amino acid having 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or more sequence identity with the amino acid sequence of SEQ ID NO: 2. Contains or consists of the nucleic acid sequence encoding the sequence. In another embodiment, the COL7A1 gene is 1-30, 1-20, 1-10, 1-5, 1-3, 1-2 or 1 in the amino acid sequence of SEQ ID NO: 2. The amino acid residue comprises or consists of a nucleic acid sequence encoding an inserted, deleted, substituted, or added amino acid sequence.
- sequence identity with respect to a nucleic acid sequence or amino acid sequence coincides between two sequences that are optimally aligned (maximum match) over the entire region of the sequence to be compared. Means the proportion of base or amino acid residues.
- sequence to be compared may have insertions, additions or deletions (eg, gaps, etc.) in the optimal alignment of the two sequences.
- Sequence identity can be calculated using programs such as FASTA, BLAST, and CLUSTAL W provided in public databases (eg, DDBJ (http://www.ddbj.nig.ac.jp)). Alternatively, it can be obtained by using commercially available sequence analysis software (for example, Vector NTI (registered trademark) software, GENETYX (registered trademark) ver. 12).
- cells are genetically modified by genome editing such as CRISPR systems (eg, CRISPR / Cas9, CRISPR / Cpf1), TALENs, ZFNs.
- CRISPR systems eg, CRISPR / Cas9, CRISPR / Cpf1
- TALENs TALENs
- ZFNs ZFNs.
- the cell is genetically modified by a viral vector such as a retroviral vector, a lentiviral vector, an adenoviral vector, an adeno-associated virus vector.
- the cells are genetically modified by CRISPR / Cas9.
- the cells are genetically modified with a retroviral vector or a lentiviral vector.
- the sequence can be inserted into the cleavage site of the genome by causing cleavage in the genome and introducing a donor vector containing the target sequence into the cell.
- the sequence to be inserted into the genome can be the COL7A1 gene, or a sequence for replacement with a site containing a mutation in the COL7A1 gene (eg, a partial sequence of the COL7A1 gene).
- the donor vector may contain regulatory sequences such as promoters and enhancers that control the expression of the sequence of interest, as well as other elements such as drug resistance genes for cell selection, at both ends of the genome. It may contain homologous sequences at both ends of the insertion site.
- the donor vector can be introduced at the desired site by non-homologous end binding or homologous recombination.
- a viral vector such as a plasmid, an adeno-associated virus vector, or an integrase-deficient lentivirus vector can be used.
- endonucleases such as Cas9 or Cas12 (eg, Cas12a (also known as Cpf1), Cas12b, Cas12e) recognize the PAM sequence, which is a specific base sequence, and the action of the endonuclease double-strands the target DNA. To disconnect. If the endonuclease is Cas9, it cleaves about 3-4 bases upstream of the PAM sequence.
- endonucleases include S. pyogenes, S. aureus, N. meningitidis, S. thermophilus, or T. denticola Cas9, L. bacterium ND2006 or Acidaminococcus sp. BV3L6 Cpfl.
- the PAM sequence is endonuclease dependent, for example, the PAM sequence of Cas9 in S. pyogenes is NGG.
- the gRNA contains a sequence (target sequence) of about 20 bases upstream of the PAM sequence or a sequence complementary thereto on the 5'end side, and plays a role of recruiting endonucleases to the target sequence.
- the sequence of the portion of the gRNA other than the target sequence (or a sequence complementary thereto) can be appropriately determined by those skilled in the art depending on the endonuclease used.
- gRNA is a crRNA (CRISPRRNA) that contains a target sequence or a sequence complementary to it and is responsible for the sequence specificity of gRNA, and a tracrRNA (Trans-activating crRNA) that forms a double strand and contributes to the formation of a complex with Cas9. And can be included.
- crRNA and tracrRNA may exist as different molecules.
- the endonuclease is Cpf1
- crRNA alone functions as a gRNA.
- a gRNA containing an element necessary for the function of the gRNA on a single strand may be particularly referred to as sgRNA.
- the gRNA sequence can be determined by tools available for target sequence selection and gRNA design, such as CRISPRdirect (https://crispr.dbcls.jp/).
- a vector containing a nucleic acid sequence encoding a gRNA and a nucleic acid sequence encoding an endonuclease may be introduced and expressed in the cell, or an extracellularly prepared gRNA and an endonuclease protein may be introduced into the cell. ..
- the endonuclease may include a nuclear localization signal.
- the nucleic acid sequence encoding the gRNA and the nucleic acid sequence encoding the endonuclease may be present on different vectors.
- Vectors, gRNAs, and endonucleases can be introduced into cells by lipofection, electroporation, microinjection, calcium phosphate method, DEAE-dextran method, etc., but are not limited to these methods.
- the gRNA that can be used to introduce the COL7A1 gene into the genome comprises any of the sequences of SEQ ID NOs: 3-5 or a sequence complementary thereto.
- the COL7A1 gene can be introduced into the cell genome by using a retroviral vector or a lentiviral vector having integrase activity.
- the retroviral vector and the lentiviral vector may be integrase-deficient. Integrase-deficient vectors lack integrase activity, for example, due to mutations in the integrase gene.
- an integrase-deficient vector, an adenovirus vector, or an adeno-associated virus vector is used, the sequence integrated into the vector is usually not introduced into the cell genome.
- type VII collagen is expressed from the COL7A1 gene of the vector existing in the cell (intranuclear).
- the viral vector contains a sequence encoding the COL7A1 gene, and may contain regulatory sequences such as promoters and enhancers that control the expression of the COL7A1 gene, and other elements such as drug resistance genes for cell selection.
- the viral vector may be prepared by any method known in the art.
- retroviral and lentiviral vectors are viral vector plasmids containing LTR sequences (5'LTR and 3'LTR) at both ends, packaging signals, and sequences of interest, viral structures such as Gag, Pol, Env. It can be made by introducing into packaging cells with one or more plasmid vectors expressing the proteins, or by introducing into packaging cells expressing these structural proteins.
- the packaging cells include, but are not limited to, 293T cells, 293 cells, HeLa cells, COS1 cells, COS7 cells, and the like.
- the viral vector may be pseudotyped and may express an enveloped protein such as, for example, the vesicular stomatitis virus G protein (VSV-G).
- VSV-G vesicular stomatitis virus G protein
- the viral vector is a lentiviral vector.
- Lentivirus vectors include HIV (human immunodeficiency virus) (for example, HIV-1 and HIV-2), SIV (simian immunodeficiency virus), FIV (feline immunodeficiency virus), MVV (Maedi-Visna virus), EV1 (Maedi-). Visna-like virus), EIAV (equine infectious anemia virus), and CAEV (caprine arthritis encephalitis virus), but are not limited to these.
- the lentiviral vector is HIV.
- the lentiviral vector can be produced as follows. First, a viral vector plasmid encoding the viral genome and one or more plasmid vectors expressing Gag, Pol, and Rev (and optionally Tat) and one or more plasmid vectors expressing enveloped proteins such as VSV-G. , Introduced into packaging cells. Viral vector plasmids are LTR sequences at both ends (5'LTR and 3'LTR), packaging signals, and promoters that control the COL7A1 gene and its expression (eg, CMV promoter, CAG promoter, EF1 ⁇ promoter, PGK promoter, or hCEF). Promoter) is included.
- LTR sequences at both ends 5'LTR and 3'LTR
- promoters that control the COL7A1 gene and its expression (eg, CMV promoter, CAG promoter, EF1 ⁇ promoter, PGK promoter, or hCEF). Promoter) is included.
- the 5'LTR functions as a promoter that induces transcription of the viral RNA genome, it may be replaced with another promoter such as the CMV promoter in order to enhance the expression of the RNA genome.
- the viral RNA genome is transcribed from the vector plasmid and packaged to form the viral core.
- the virus core is transported to the cell membrane of the packaging cell, encapsulated in the cell membrane, and released as virus particles from the packaging cell.
- the released virus particles can be recovered from the culture supernatant of the packaging cells.
- virus particles can be recovered by conventional purification methods such as centrifugation, filter filtration, column purification and the like.
- lentiviral vectors can be manufactured using kits such as Lentiviral High Titer Packaging Mix, Lenti-X TM Packaging Single Shots (Takara Bio Inc.), and ViraSafe TM Lentivirus Complete Expression System (Cell Biolabs Inc.). can.
- Adeno-associated virus vectors can be prepared using a kit such as AAVpro (R) Helper Free System (Takara Bio Inc. ).
- the cells into which the target sequence has been introduced can be confirmed by Southern blotting or PCR.
- the sequence of interest may be introduced into at least one of the alleles.
- DEB patient blister-derived cells are the most abundant cells contained in the composition.
- DEB patient blister-derived cells make up 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98 or 99% or more of the cells contained in the composition.
- the compositions of the present disclosure are substantially free of cells other than DEB patient blister-derived cells. "Substantially free of cells other than DEB patient blister-derived cells” means that only cells obtained by substantially the same method as the method for obtaining DEB patient blister-derived cells described herein are included. means.
- the number of cells contained in the composition is an amount required to exert the desired effect (also referred to herein as an effective amount), and those skilled in the art will appreciate the age, weight, and medical condition of the patient, as well as the type of cells. It can be appropriately determined in consideration of factors such as the gene modification method.
- the number of cells is not limited, but is, for example, 1 cell to 1 ⁇ 10 7 cells, 1 ⁇ 10 cells to 1 ⁇ 10 7 cells, 1 ⁇ 10 2 cells to 1 ⁇ 10 7 cells, 1 ⁇ 10 3 cells to 1 ⁇ .
- composition may include pharmaceutically acceptable vehicles and / or additives in addition to the cells.
- Pharmaceutically acceptable vehicles include water, medium, saline, glucose, infusions containing D-sorbitol, D-mannitol and the like, phosphate buffered saline (PBS) and the like.
- PBS phosphate buffered saline
- the additive include a solubilizing agent, a stabilizer, a preservative and the like.
- the dosage form of the composition is not particularly limited, but is a parenteral administration preparation, for example, an injection.
- Injections include solution injections, suspension injections, emulsion injections, and time-prepared injections.
- the composition may be frozen or may contain cryoprotectants such as DMSO, glycerol, polyvinylpyrrolidone, polyethylene glycol, dextran, sucrose and the like.
- compositions of the present disclosure may be administered systemically or topically.
- the composition is administered to the affected area of a nutritionally impaired epidermolysis bullosa patient.
- the affected area means a blister or an area in the vicinity thereof.
- the composition is administered intracutaneously or intrablister of the blister portion.
- the composition is administered intrablister.
- administration in the blister means administration in the space under the epidermis of the blister portion. Intrablister administration can reduce patient distress as compared to intradermal or subcutaneous administration, and type VII collagen can be well expressed near the basement membrane.
- the number of cells administered per site is an amount (effective amount) necessary for exerting the desired effect, and those skilled in the art will be able to determine the patient's age, weight, and medical condition, as well as the cell type and gene modification method. It can be determined as appropriate in consideration of the factors of.
- the number of cells is not limited, but for example, 1 cell to 1 ⁇ 10 7 cells, 1 ⁇ 10 cells to 1 ⁇ 10 7 cells, 1 ⁇ 10 2 cells to 1 ⁇ 10 7 cells, 1 ⁇ 10 3 cells to 1 ⁇ 10 7 cells, 1 ⁇ 10 4 cells to 1 ⁇ 10 7 cells, 1 ⁇ 10 5 cells to 1 ⁇ 10 7 cells, 1 ⁇ 10 5 cells to 5 ⁇ 10 6 cells, 5 ⁇ 10 5 cells to 1 ⁇ 10 6 cells, or 1 x 10 5 cells to 1 x 10 6 cells.
- the dose per blister may be a standard blister having a diameter of 7 to 8 mm when the blister is approximately circularly approximated, and the above dose may be adjusted according to the size thereof.
- a composition for use in the treatment of dystrophic epidermolysis bullosa comprising blister-derived cells of a dystrophic epidermolysis bullosa patient genetically modified to produce type VII collagen.
- the composition according to 1 above, wherein the blister-derived cells have been genetically modified by introducing the COL7A1 gene.
- the COL7A1 gene contains a nucleic acid sequence having 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or more sequence identity with the nucleic acid sequence of SEQ ID NO: 1 Containing a nucleic acid sequence encoding an amino acid sequence having 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or more sequence identity with the amino acid sequence of SEQ ID NO: 2.
- composition according to any one of 1 to 4 above, wherein the blister-derived cells have one or more characteristics selected from the following 1) to 6): 1) Adhesive to the solid phase, 2) One or more surface markers selected from the group consisting of CD73, CD105 and CD90 are positive. 3) One or more surface markers selected from the group consisting of CD45, CD34, CD11b, CD79A, HLA-DR and CD31 are negative, 4) It does not have the ability to differentiate into osteoblasts, or its differentiation ability is lower than that of bone marrow-derived mesenchymal stem cells. 5) It does not have the ability to differentiate into adipocytes, or its differentiation ability is lower than that of bone marrow-derived mesenchymal stem cells.
- the composition according to any one of 1 to 10 above, wherein the blister-derived cells have been genetically modified by genome editing.
- composition according to 11 above wherein the genome editing is performed by CRISPR / Cas9.
- composition according to any one of 1 to 10 above, wherein the blister-derived cells are genetically modified by a viral vector.
- the viral vector is a retrovirus vector or a lentiviral vector.
- the viral vector is a lentiviral vector.
- a method for producing a composition for use in the treatment of nutritionally impaired epidermolysis bullosa comprising genetically modifying a blister-derived cell of a dystrophic epidermolysis bullosa patient to produce type VII collagen, and preparing a composition comprising the genetically modified blister-derived cell.
- a method for treating dystrophic epidermolysis bullosa wherein a composition containing blister-derived cells of a dystrophic epidermolysis bullosa patient genetically modified to produce type VII collagen is administered to the patient. How to include.
- [18] 17 The method according to 17 above, wherein the blister-derived cells have been genetically modified by introducing the COL7A1 gene. [19] 18.
- the method according to 18 above wherein the COL7A1 gene has been introduced into the genome of a blister-derived cell.
- the COL7A1 gene contains a nucleic acid sequence having 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or more sequence identity with the nucleic acid sequence of SEQ ID NO: 1 Containing a nucleic acid sequence encoding an amino acid sequence having 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or more sequence identity with the amino acid sequence of SEQ ID NO: 2.
- the method of any of 16 and 26-29 above, wherein the blister-derived cells are genetically modified by genome editing.
- the viral vector is a lentiviral vector.
- composition comprising blister-derived cells of a dystrophy-type epidermolysis bullosa patient genetically modified to produce type VII collagen for the manufacture of a pharmaceutical for the treatment of dystrophic epidermolysis bullosa.
- 41 The use according to 41, wherein the composition is administered intrablister.
- a gRNA comprising any of the sequences of SEQ ID NOs: 3 to 5 or a sequence complementary thereto.
- a method for producing cells which comprises a step of culturing the contents of blisters of a patient with epidermolysis bullosa with malnutrition on a solid phase.
- the cell according to 50 which has one or more characteristics selected from 1) to 6) below: 1) Adhesive to the solid phase, 2) One or more surface markers selected from the group consisting of CD73, CD105 and CD90 are positive.
- One or more surface markers selected from the group consisting of CD45, CD34, CD11b, CD79A, HLA-DR and CD31 are negative, 4) It does not have the ability to differentiate into osteoblasts, or its differentiation ability is lower than that of bone marrow-derived mesenchymal stem cells. 5) It does not have the ability to differentiate into adipocytes, or its differentiation ability is lower than that of bone marrow-derived mesenchymal stem cells. 6) It does not have the ability to differentiate into chondrocytes, or its differentiation ability is lower than that of bone marrow-derived mesenchymal stem cells.
- [52] Cell production method including the following steps: 1) The process of culturing the contents of blisters in patients with epidermolysis bullosa with malnutrition on a solid phase, 2) Culture step A step of genetically modifying the cells obtained in 1) to produce type VII collagen.
- the cell according to 53 or 54 above which has been genetically modified by introducing the COL7A1 gene.
- the COL7A1 gene contains a nucleic acid sequence having 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or more sequence identity with the nucleic acid sequence of SEQ ID NO: 1 Containing a nucleic acid sequence encoding an amino acid sequence having 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or more sequence identity with the amino acid sequence of SEQ ID NO: 2.
- the cell according to 56 [58] The cell according to any one of 53 to 57 above, which has been genetically modified by genome editing. [59] The cell according to 58 above, wherein the genome editing was performed by CRISPR / Cas9.
- One or more surface markers selected from the group consisting of CD45, CD34, CD11b, CD79A, HLA-DR and CD31 are negative, 4) It does not have the ability to differentiate into osteoblasts, or its differentiation ability is lower than that of bone marrow-derived mesenchymal stem cells. 5) It does not have the ability to differentiate into adipocytes, or its differentiation ability is lower than that of bone marrow-derived mesenchymal stem cells. 6) It does not have the ability to differentiate into chondrocytes, or its differentiation ability is lower than that of bone marrow-derived mesenchymal stem cells.
- the cells obtained by such a method are also referred to as "blister-derived cells” below.
- the following surface marker analysis and differentiation induction experiments used cells of the 3rd passage, and cells of the 3rd to 4th passages were used for gene transfer.
- an equal amount mixed medium of Mesenchymal Stem Cell Growth Medium 2 (PromoCell, C-28009) and MSCGM Mesenchymal Stem Cell Growth Medium (Lonza, PT-3001) or Cellartis MSC Xeno-Free Culture It was confirmed that equivalent blisters-derived cells could be obtained even when Medium (Takara Bio Inc., Y50200) was used.
- Blister-derived cell characterization a) Surface marker analysis (FACS) Regarding the blisters-derived cells obtained in 1. above and human bone marrow-derived mesenchymal stem cells (hereinafter, also referred to as BM-MSC) [purchased from PromoCell (Heidelberg, Germany) or Lonza (Basel, Switzerland)], the following. Surface marker analysis was performed according to the procedure of: Cells were peeled from the plate using Accutase-Solution (PromoCell, C-41310), washed with medium, and then placed in two tubes based on the cell count measurement results. 100,000 cells were separated.
- FACS Surface marker analysis
- the cells were washed once with 2 ml of Flow Cytometry Staining Buffer (1X), resuspended in 300 ⁇ l of Flow Cytometry Staining Buffer (1X), and then analyzed with BD FACSAria (BD). FACS analysis was also performed on CD31 according to the following procedure to confirm the presence or absence of expression in blister-derived cells and human BM-MSC: cells were peeled from the plate using Accutase-Solution (PromoCell, C-41310), and the medium was used. After washing with, 100,000 cells were separated into two tubes based on the measurement result of the cell number.
- BD FACSAria BD FACSAria
- both blister-derived cells and BM-MSC were positive for CD73, CD105 and CD90, and negative for CD45, CD34, CD11b, CD79A, HLA-DR and CD31 (Fig. 2).
- Induction of differentiation (osteoblasts, adipocytes and chondrocytes)
- the blisters-derived cells and BM-MSC obtained in 1. above were induced to differentiate into osteoblasts, adipocytes and chondrocytes under the following conditions.
- Induction of differentiation into osteoblasts Cells are cultured in medium containing 0.1 ⁇ M Dexamethasone, 0.2 mM Ascorbic acid 2-phosphate, 10 mM Glycerol 2-phosphate (all numerical values are final concentrations) at 37 ° C. and 5% CO 2 for 3 weeks (2 weeks). (Culture exchange) was performed to induce differentiation into osteoblasts.
- Alkaline phosphatase (ALP) staining was performed using the TRACP & ALP Assay Kit (Takara Bio Inc., MK301) according to the product manual.
- Induction of differentiation into adipocytes Cells were cultivated in medium containing 1 ⁇ M Dexamethasone, 0.5 mM 3-Isobutyl-1-methylanxthine (IBMX), 10 ⁇ g / mL Insulin, 100 ⁇ M Indomethacin (all numbers are final concentrations) under 37 ° C., 5% CO 2 conditions. Insulin differentiation into adipocytes was induced by culturing for 3 weeks (medium exchange twice a week).
- the cells were stained with Oil Red O using the Lipit assay kit (Cosmo Bio Co., Ltd., AK09F) according to the product manual.
- Induction of differentiation into chondrocytes The components of Human Mesenchymal Stem Cell (hMSC) Chondrogenic Differentiation Medium Bullet Kit (tm) (Lonza, PT-3003) were mixed as instructed to prepare a cartilage differentiation-inducing medium (incomplete medium).
- Recombinant Human TGF-beta 3 Protein R & D Systems, 243-B3 was added to this to a final concentration of 10 ng / ml, and a cartilage differentiation-inducing medium (complete medium) was prepared for each use.
- the third passage cells were peeled off with Accutase-Solution PromoCell (C-41310), washed with a medium, and then 250,000 cells were separated into 15 ml polypropylene conical tubes based on the cell number measurement results.
- the cells were washed twice with cartilage differentiation-inducing medium (incomplete medium), the supernatant was removed, and then suspended in 500 ⁇ l of cartilage differentiation-inducing medium (complete medium).
- Cell pellets were formed by centrifugation at 150 g for 5 minutes, the lid was loosened and placed in a CO 2 incubator (37 ° C, 5% CO 2 ), and then the medium (complete medium) was changed every 2 to 3 days.
- the pellet was taken out and fixed with 4% paraformaldehyde, frozen sections were prepared, and chondrocyte-derived proteoglycan was stained by Alcian blue staining.
- chondrocyte-derived proteoglycan was stained by Alcian blue staining.
- the same differentiation-inducing operation was performed on human bone marrow-derived mesenchymal stem cells.
- BM-MSC was positive in all of ALP staining, Oil Red O staining, and Alcian blue staining.
- blistering-derived cells were positive for ALP staining (however, the staining intensity was lower than BM-MSC), positive for Oil Red O staining (however, the staining intensity was lower than that for BM-MSC), and negative for alcyan blue staining. There was (Fig. 3).
- sgRNAs Three types were prepared in order to select a position in the human genome that has good cleavage efficiency by the CRISPR-Cas9 system in the AAVS1 (Adeno-associated virus integration site 1) region.
- the AAVS1 region is a safe region (safe harbor) that is not easily affected by gene transfer. Since the CRISPR-Cas9 system recognizes the base sequence of "NGG” and cleaves 3 bases upstream of it, it selects the region where "GG" is located at the end and selects the target sequence of 20 bases upstream of "NGG". Included sgRNAs (sgAAVS1- # 1 to # 3) were designed (Fig. 4, top; Table 1).
- a plasmid expressing the Cas9 protein and sgRNA was prepared by cloning the oligonucleotide consisting of any of SEQ ID NOs: 3 to 5 and its complementary strand into the Bbs1 site of eSpCas9 (1.1) (Addgene plasmid # 71814). Created (eSpCas9 (1.1)-sgAAVS1- # 1, eSpCas9 (1.1)-sgAAVS1- # 2, eSpCas9 (1.1)-sgAAVS1- # 3, respectively).
- This plasmid (2.5 ⁇ g) was introduced into HEK293 cells (human fetal kidney cell line) seeded in 6 well dishes by Lipofectamin 3000 (Thermo Fisher Scientific). Forty-eight hours after transfection, genomic DNA was extracted from the cells and the region containing the target site was amplified by PCR. The PCR amplified fragments were single-stranded by heat treatment, annealed by slow cooling, and then treated with a mismatch site-specific endonuclease. This was fractionated by electrophoresis, the degree of insertion or deletion mutation introduced by genome cleavage was measured by the band density, and the genome editing efficiency was calculated by the following formula (in the formula, a is digested). Band concentration that was not present, b and c indicate the band concentration that was cleaved).
- COL7A1 gene into blister-derived cells
- a plasmid expressing the COL7A1 gene was designed under the control of the CAG promoter (Fig. 5).
- the COL7A1 cDNA was obtained from the Flexi ORF sequence-verified clone (Promega, Madison, WI, USA).
- the COL7A1 cDNA was subcloned into the pENTR1A plasmid (Thermo Fisher Scientific, A10462) to give pENTR1A-COL7A1.
- COL7A1 cDNA was introduced from pENTR1A-COL7A1 to pAAVS1-P-CAG-DEST (Addgene plasmid # 80490) by Gateway reaction using LR recombinase (Thermo Fisher Scientific) to obtain donor plasmid pAAVS1-P-CAG-COL7A1.
- the blister-derived cells obtained in 1. above were suspended in a dedicated buffer of the Neon transfection system (Thermo Fisher Scientific), and the Cas9-sgRNA expression plasmid (eSpCas9 (1.1) -sgAAVS1- # 3) and donor plasmid (pAAVS1-P) were suspended.
- eSpCas9 1.1
- pAAVS1-P donor plasmid
- the above plasmid was introduced into blister-derived cells by electroporation under the conditions of 1,200 V, 20 ms, and 2 pulses, and then seeded and cultured on a 6-well plate.
- As the medium an equal amount mixed medium of Mesenchymal Stem Cell Growth Medium 2 (PromoCell, C-28009) and MSCGM Mesenchymal Stem Cell Growth Medium (Lonza, PT-3001) was used. Puromycin was added to a final concentration of 0.5 ⁇ g / mL 48 hours after transfection, cultured for about 2 weeks, and the selected cells were used in the transplantation experiment into the following mice.
- the blister-derived cells have a higher expression level and secretion amount of type VII collagen than BM-MSC and fibroblasts. Therefore, blister-derived cells into which the COL7A1 gene has been introduced are expected to exert a higher therapeutic effect than BM-MSC and fibroblasts in gene therapy for dystrophic epidermolysis bullosa.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本開示は、栄養障害型表皮水疱症の治療薬に関する。
1)固相への接着性を有する、
2)CD73、CD105およびCD90からなる群より選択される一つ以上の表面マーカーが陽性である、
3)CD45、CD34、CD11b、CD79A、HLA-DRおよびCD31からなる群より選択される一つ以上の表面マーカーが陰性である、
4)骨芽細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い、
5)脂肪細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い、
6)軟骨細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い。
本開示において、ある細胞が骨芽細胞、脂肪細胞または軟骨細胞への「分化能を有しない」とは、通常の分化誘導条件および検出方法(染色等)を用いて骨芽細胞、脂肪細胞または軟骨細胞への分化を検出できないことを意味する。
ヒトCOL7A1遺伝子のcDNA配列(8835 bp)(配列番号1)
ATGACGCTGCGGCTTCTGGTGGCCGCGCTCTGCGCCGGGATCCTGGCAGAGGCGCCCCGAGTGCGAGCCCAGCACAGGGAGAGAGTGACCTGCACGCGCCTTTACGCCGCTGACATTGTGTTCTTACTGGATGGCTCCTCATCCATTGGCCGCAGCAATTTCCGCGAGGTCCGCAGCTTTCTCGAAGGGCTGGTGCTGCCTTTCTCTGGAGCAGCCAGTGCACAGGGTGTGCGCTTTGCCACAGTGCAGTACAGCGATGATCCACGGACAGAGTTCGGCCTGGATGCACTTGGCTCTGGGGGTGATGTGATCCGCGCCATCCGTGAGCTTAGCTACAAGGGGGGCAACACTCGCACAGGGGCTGCAATTCTCCATGTGGCTGACCATGTCTTCCTGCCCCAGCTGGCCCGACCTGGTGTCCCCAAGGTCTGCATCCTGATCACAGACGGGAAGTCCCAGGACCTGGTGGACACAGCTGCCCAAAGGCTGAAGGGGCAGGGGGTCAAGCTATTTGCTGTGGGGATCAAGAATGCTGACCCTGAGGAGCTGAAGCGAGTTGCCTCACAGCCCACCAGTGACTTCTTCTTCTTCGTCAATGACTTCAGCATCTTGAGGACACTACTGCCCCTCGTTTCCCGGAGAGTGTGCACGACTGCTGGTGGCGTGCCTGTGACCCGACCTCCGGATGACTCGACCTCTGCTCCACGAGACCTGGTGCTGTCTGAGCCAAGCAGCCAATCCTTGAGAGTACAGTGGACAGCGGCCAGTGGCCCTGTGACTGGCTACAAGGTCCAGTACACTCCTCTGACGGGGCTGGGACAGCCACTGCCGAGTGAGCGGCAGGAGGTGAACGTCCCAGCTGGTGAGACCAGTGTGCGGCTGCGGGGTCTCCGGCCACTGACCGAGTACCAAGTGACTGTGATTGCCCTCTACGCCAACAGCATCGGGGAGGCTGTGAGCGGGACAGCTCGGACCACTGCCCTAGAAGGGCCGGAACTGACCATCCAGAATACCACAGCCCACAGCCTCCTGGTGGCCTGGCGGAGTGTGCCAGGTGCCACTGGCTACCGTGTGACATGGCGGGTCCTCAGTGGTGGGCCCACACAGCAGCAGGAGCTGGGCCCTGGGCAGGGTTCAGTGTTGCTGCGTGACTTGGAGCCTGGCACGGACTATGAGGTGACCGTGAGCACCCTATTTGGCCGCAGTGTGGGGCCCGCCACTTCCCTGATGGCTCGCACTGACGCTTCTGTTGAGCAGACCCTGCGCCCGGTCATCCTGGGCCCCACATCCATCCTCCTTTCCTGGAACTTGGTGCCTGAGGCCCGTGGCTACCGGTTGGAATGGCGGCGTGAGACTGGCTTGGAGCCACCGCAGAAGGTGGTACTGCCCTCTGATGTGACCCGCTACCAGTTGGATGGGCTGCAGCCGGGCACTGAGTACCGCCTCACACTCTACACTCTGCTGGAGGGCCACGAGGTGGCCACCCCTGCAACCGTGGTTCCCACTGGACCAGAGCTGCCTGTGAGCCCTGTAACAGACCTGCAAGCCACCGAGCTGCCCGGGCAGCGGGTGCGAGTGTCCTGGAGCCCAGTCCCTGGTGCCACCCAGTACCGCATCATTGTGCGCAGCACCCAGGGGGTTGAGCGGACCCTGGTGCTTCCTGGGAGTCAGACAGCATTCGACTTGGATGACGTTCAGGCTGGGCTTAGCTACACTGTGCGGGTGTCTGCTCGAGTGGGTCCCCGTGAGGGCAGTGCCAGTGTCCTCACTGTCCGCCGGGAGCCGGAAACTCCACTTGCTGTTCCAGGGCTGCGGGTTGTGGTGTCAGATGCAACGCGAGTGAGGGTGGCCTGGGGACCCGTCCCTGGAGCCAGTGGATTTCGGATTAGCTGGAGCACAGGCAGTGGTCCGGAGTCCAGCCAGACACTGCCCCCAGACTCTACTGCCACAGACATCACAGGGCTGCAGCCTGGAACCACCTACCAGGTGGCTGTGTCGGTACTGCGAGGCAGAGAGGAGGGCCCTGCTGCAGTCATCGTGGCTCGAACGGACCCACTGGGCCCAGTGAGGACGGTCCATGTGACTCAGGCCAGCAGCTCATCTGTCACCATTACCTGGACCAGGGTTCCTGGCGCCACAGGATACAGGGTTTCCTGGCACTCAGCCCACGGCCCAGAGAAATCCCAGTTGGTTTCTGGGGAGGCCACGGTGGCTGAGCTGGATGGACTGGAGCCAGATACTGAGTATACGGTGCATGTGAGGGCCCATGTGGCTGGCGTGGATGGGCCCCCTGCCTCTGTGGTTGTGAGGACTGCCCCTGAGCCTGTGGGTCGTGTGTCGAGGCTGCAGATCCTCAATGCTTCCAGCGACGTTCTACGGATCACCTGGGTAGGGGTCACTGGAGCCACAGCTTACAGACTGGCCTGGGGCCGGAGTGAAGGCGGCCCCATGAGGCACCAGATACTCCCAGGAAACACAGACTCTGCAGAGATCCGGGGTCTCGAAGGTGGAGTCAGCTACTCAGTGCGAGTGACTGCACTTGTCGGGGACCGCGAGGGCACACCTGTCTCCATTGTTGTCACTACGCCGCCTGAGGCTCCGCCAGCCCTGGGGACGCTTCACGTGGTGCAGCGCGGGGAGCACTCGCTGAGGCTGCGCTGGGAGCCGGTGCCCAGAGCGCAGGGCTTCCTTCTGCACTGGCAACCTGAGGGTGGCCAGGAACAGTCCCGGGTCCTGGGGCCCGAGCTCAGCAGCTATCACCTGGACGGGCTGGAGCCAGCGACACAGTACCGCGTGAGGCTGAGTGTCCTAGGGCCAGCTGGAGAAGGGCCCTCTGCAGAGGTGACTGCGCGCACTGAGTCACCTCGTGTTCCAAGCATTGAACTACGTGTGGTGGACACCTCGATCGACTCGGTGACTTTGGCCTGGACTCCAGTGTCCAGGGCATCCAGCTACATCCTATCCTGGCGGCCACTCAGAGGCCCTGGCCAGGAAGTGCCTGGGTCCCCGCAGACACTTCCAGGGATCTCAAGCTCCCAGCGGGTGACAGGGCTAGAGCCTGGCGTCTCTTACATCTTCTCCCTGACGCCTGTCCTGGATGGTGTGCGGGGTCCTGAGGCATCTGTCACACAGACGCCAGTGTGCCCCCGTGGCCTGGCGGATGTGGTGTTCCTACCACATGCCACTCAAGACAATGCTCACCGTGCGGAGGCTACGAGGAGGGTCCTGGAGCGTCTGGTGTTGGCACTTGGGCCTCTTGGGCCACAGGCAGTTCAGGTTGGCCTGCTGTCTTACAGTCATCGGCCCTCCCCACTGTTCCCACTGAATGGCTCCCATGACCTTGGCATTATCTTGCAAAGGATCCGTGACATGCCCTACATGGACCCAAGTGGGAACAACCTGGGCACAGCCGTGGTCACAGCTCACAGATACATGTTGGCACCAGATGCTCCTGGGCGCCGCCAGCACGTACCAGGGGTGATGGTTCTGCTAGTGGATGAACCCTTGAGAGGTGACATATTCAGCCCCATCCGTGAGGCCCAGGCTTCTGGGCTTAATGTGGTGATGTTGGGAATGGCTGGAGCGGACCCAGAGCAGCTGCGTCGCTTGGCGCCGGGTATGGACTCTGTCCAGACCTTCTTCGCCGTGGATGATGGGCCAAGCCTGGACCAGGCAGTCAGTGGTCTGGCCACAGCCCTGTGTCAGGCATCCTTCACTACTCAGCCCCGGCCAGAGCCCTGCCCAGTGTATTGTCCAAAGGGCCAGAAGGGGGAACCTGGAGAGATGGGCCTGAGAGGACAAGTTGGGCCTCCTGGCGACCCTGGCCTCCCGGGCAGGACCGGTGCTCCCGGCCCCCAGGGGCCCCCTGGAAGTGCCACTGCCAAGGGCGAGAGGGGCTTCCCTGGAGCAGATGGGCGTCCAGGCAGCCCTGGCCGCGCCGGGAATCCTGGGACCCCTGGAGCCCCTGGCCTAAAGGGCTCTCCAGGGTTGCCTGGCCCTCGTGGGGACCCGGGAGAGCGAGGACCTCGAGGCCCAAAGGGGGAGCCGGGGGCTCCCGGACAAGTCATCGGAGGTGAAGGACCTGGGCTTCCTGGGCGGAAAGGGGACCCTGGACCATCGGGCCCCCCTGGACCTCGTGGACCACTGGGGGACCCAGGACCCCGTGGCCCCCCAGGGCTTCCTGGAACAGCCATGAAGGGTGACAAAGGCGATCGTGGGGAGCGGGGTCCCCCTGGACCAGGTGAAGGTGGCATTGCTCCTGGGGAGCCTGGGCTGCCGGGTCTTCCCGGAAGCCCTGGACCCCAAGGCCCCGTTGGCCCCCCTGGAAAGAAAGGAGAAAAAGGTGACTCTGAGGATGGAGCTCCAGGCCTCCCAGGACAACCTGGGTCTCCGGGTGAGCAGGGCCCACGGGGACCTCCTGGAGCTATTGGCCCCAAAGGTGACCGGGGCTTTCCAGGGCCCCTGGGTGAGGCTGGAGAGAAGGGCGAACGTGGACCCCCAGGCCCAGCGGGATCCCGGGGGCTGCCAGGGGTTGCTGGACGTCCTGGAGCCAAGGGTCCTGAAGGGCCACCAGGACCCACTGGCCGCCAAGGAGAGAAGGGGGAGCCTGGTCGCCCTGGGGACCCTGCAGTGGTGGGACCTGCTGTTGCTGGACCCAAAGGAGAAAAGGGAGATGTGGGGCCCGCTGGGCCCAGAGGAGCTACCGGAGTCCAAGGGGAACGGGGCCCACCCGGCTTGGTTCTTCCTGGAGACCCTGGCCCCAAGGGAGACCCTGGAGACCGGGGTCCCATTGGCCTTACTGGCAGAGCAGGACCCCCAGGTGACTCAGGGCCTCCTGGAGAGAAGGGAGACCCTGGGCGGCCTGGCCCCCCAGGACCTGTTGGCCCCCGAGGACGAGATGGTGAAGTTGGAGAGAAAGGTGACGAGGGTCCTCCGGGTGACCCGGGTTTGCCTGGAAAAGCAGGCGAGCGTGGCCTTCGGGGGGCACCTGGAGTTCGGGGGCCTGTGGGTGAAAAGGGAGACCAGGGAGATCCTGGAGAGGATGGACGAAATGGCAGCCCTGGATCATCTGGACCCAAGGGTGACCGTGGGGAGCCGGGTCCCCCAGGACCCCCGGGACGGCTGGTAGACACAGGACCTGGAGCCAGAGAGAAGGGAGAGCCTGGGGACCGCGGACAAGAGGGTCCTCGAGGGCCCAAGGGTGATCCTGGCCTCCCTGGAGCCCCTGGGGAAAGGGGCATTGAAGGGTTTCGGGGACCCCCAGGCCCACAGGGGGACCCAGGTGTCCGAGGCCCAGCAGGAGAAAAGGGTGACCGGGGTCCCCCTGGGCTGGATGGCCGGAGCGGACTGGATGGGAAACCAGGAGCCGCTGGGCCCTCTGGGCCGAATGGTGCTGCAGGCAAAGCTGGGGACCCAGGGAGAGACGGGCTTCCAGGCCTCCGTGGAGAACAGGGCCTCCCTGGCCCCTCTGGTCCCCCTGGATTACCGGGAAAGCCAGGCGAGGATGGCAAACCTGGCCTGAATGGAAAAAACGGAGAACCTGGGGACCCTGGAGAAGACGGGAGGAAGGGAGAGAAAGGAGATTCAGGCGCCTCTGGGAGAGAAGGTCGTGATGGCCCCAAGGGTGAGCGTGGAGCTCCTGGTATCCTTGGACCCCAGGGGCCTCCAGGCCTCCCAGGGCCAGTGGGCCCTCCTGGCCAGGGTTTTCCTGGTGTCCCAGGAGGCACGGGCCCCAAGGGTGACCGTGGGGAGACTGGATCCAAAGGGGAGCAGGGCCTCCCTGGAGAGCGTGGCCTGCGAGGAGAGCCTGGAAGTGTGCCGAATGTGGATCGGTTGCTGGAAACTGCTGGCATCAAGGCATCTGCCCTGCGGGAGATCGTGGAGACCTGGGATGAGAGCTCTGGTAGCTTCCTGCCTGTGCCCGAACGGCGTCGAGGCCCCAAGGGGGACTCAGGCGAACAGGGCCCCCCAGGCAAGGAGGGCCCCATCGGCTTTCCTGGAGAACGCGGGCTGAAGGGCGACCGTGGAGACCCTGGCCCTCAGGGGCCACCTGGTCTGGCCCTTGGGGAGAGGGGCCCCCCCGGGCCTTCCGGCCTTGCCGGGGAGCCTGGAAAGCCTGGTATTCCCGGGCTCCCAGGCAGGGCTGGGGGTGTGGGAGAGGCAGGAAGGCCAGGAGAGAGGGGAGAACGGGGAGAGAAAGGAGAACGTGGAGAACAGGGCAGAGATGGCCCTCCTGGACTCCCTGGAACCCCTGGGCCCCCCGGACCCCCTGGCCCCAAGGTGTCTGTGGATGAGCCAGGTCCTGGACTCTCTGGAGAACAGGGACCCCCTGGACTCAAGGGTGCTAAGGGGGAGCCGGGCAGCAATGGTGACCAAGGTCCCAAAGGAGACAGGGGTGTGCCAGGCATCAAAGGAGACCGGGGAGAGCCTGGACCGAGGGGTCAGGACGGCAACCCGGGTCTACCAGGAGAGCGTGGTATGGCTGGGCCTGAAGGGAAGCCGGGTCTGCAGGGTCCAAGAGGCCCCCCTGGCCCAGTGGGTGGTCATGGAGACCCTGGACCACCTGGTGCCCCGGGTCTTGCTGGCCCTGCAGGACCCCAAGGACCTTCTGGCCTGAAGGGGGAGCCTGGAGAGACAGGACCTCCAGGACGGGGCCTGACTGGACCTACTGGAGCTGTGGGACTTCCTGGACCCCCCGGCCCTTCAGGCCTTGTGGGTCCACAGGGGTCTCCAGGTTTGCCTGGACAAGTGGGGGAGACAGGGAAGCCGGGAGCCCCAGGTCGAGATGGTGCCAGTGGAAAAGATGGAGACAGAGGGAGCCCTGGTGTGCCAGGGTCACCAGGTCTGCCTGGCCCTGTCGGACCTAAAGGAGAACCTGGCCCCACGGGGGCCCCTGGACAGGCTGTGGTCGGGCTCCCTGGAGCAAAGGGAGAGAAGGGAGCCCCTGGAGGCCTTGCTGGAGACCTGGTGGGTGAGCCGGGAGCCAAAGGTGACCGAGGACTGCCAGGGCCGCGAGGCGAGAAGGGTGAAGCTGGCCGTGCAGGGGAGCCCGGAGACCCTGGGGAAGATGGTCAGAAAGGGGCTCCAGGACCCAAAGGTTTCAAGGGTGACCCAGGAGTCGGGGTCCCGGGCTCCCCTGGGCCTCCTGGCCCTCCAGGTGTGAAGGGAGATCTGGGCCTCCCTGGCCTGCCCGGTGCTCCTGGTGTTGTTGGGTTCCCGGGTCAGACAGGCCCTCGAGGAGAGATGGGTCAGCCAGGCCCTAGTGGAGAGCGGGGTCTGGCAGGCCCCCCAGGGAGAGAAGGAATCCCAGGACCCCTGGGGCCACCTGGACCACCGGGGTCAGTGGGACCACCTGGGGCCTCTGGACTCAAAGGAGACAAGGGAGACCCTGGAGTAGGGCTGCCTGGGCCCCGAGGCGAGCGTGGGGAGCCAGGCATCCGGGGTGAAGATGGCCGCCCCGGCCAGGAGGGACCCCGAGGACTCACGGGGCCCCCTGGCAGCAGGGGAGAGCGTGGGGAGAAGGGTGATGTTGGGAGTGCAGGACTAAAGGGTGACAAGGGAGACTCAGCTGTGATCCTGGGGCCTCCAGGCCCACGGGGTGCCAAGGGGGACATGGGTGAACGAGGGCCTCGGGGCTTGGATGGTGACAAAGGACCTCGGGGAGACAATGGGGACCCTGGTGACAAGGGCAGCAAGGGAGAGCCTGGTGACAAGGGCTCAGCCGGGTTGCCAGGACTGCGTGGACTCCTGGGACCCCAGGGTCAACCTGGTGCAGCAGGGATCCCTGGTGACCCGGGATCCCCAGGAAAGGATGGAGTGCCTGGTATCCGAGGAGAAAAAGGAGATGTTGGCTTCATGGGTCCCCGGGGCCTCAAGGGTGAACGGGGAGTGAAGGGAGCCTGTGGCCTTGATGGAGAGAAGGGAGACAAGGGAGAAGCTGGTCCCCCAGGCCGCCCCGGGCTGGCAGGACACAAAGGAGAGATGGGGGAGCCTGGTGTGCCGGGCCAGTCGGGGGCCCCTGGCAAGGAGGGCCTGATCGGTCCCAAGGGTGACCGAGGCTTTGACGGGCAGCCAGGCCCCAAGGGTGACCAGGGCGAGAAAGGGGAGCGGGGAACCCCAGGAATTGGGGGCTTCCCAGGCCCCAGTGGAAATGATGGCTCTGCTGGTCCCCCAGGGCCACCTGGCAGTGTTGGTCCCAGAGGCCCCGAAGGACTTCAGGGCCAGAAGGGTGAGCGAGGTCCCCCCGGAGAGAGAGTGGTGGGGGCTCCTGGGGTCCCTGGAGCTCCTGGCGAGAGAGGGGAGCAGGGGCGGCCAGGGCCTGCCGGTCCTCGAGGCGAGAAGGGAGAAGCTGCACTGACGGAGGATGACATCCGGGGCTTTGTGCGCCAAGAGATGAGTCAGCACTGTGCCTGCCAGGGCCAGTTCATCGCATCTGGATCACGACCCCTCCCTAGTTATGCTGCAGACACTGCCGGCTCCCAGCTCCATGCTGTGCCTGTGCTCCGCGTCTCTCATGCAGAGGAGGAAGAGCGGGTACCCCCTGAGGATGATGAGTACTCTGAATACTCCGAGTATTCTGTGGAGGAGTACCAGGACCCTGAAGCTCCTTGGGATAGTGATGACCCCTGTTCCCTGCCACTGGATGAGGGCTCCTGCACTGCCTACACCCTGCGCTGGTACCATCGGGCTGTGACAGGCAGCACAGAGGCCTGTCACCCTTTTGTCTATGGTGGCTGTGGAGGGAATGCCAACCGTTTTGGGACCCGTGAGGCCTGCGAGCGCCGCTGCCCACCCCGGGTGGTCCAGAGCCAGGGGACAGGTACTGCCCAGGACTGA
ヒトVII型コラーゲンのアミノ酸配列(2944 AA)(配列番号2)
MTLRLLVAALCAGILAEAPRVRAQHRERVTCTRLYAADIVFLLDGSSSIGRSNFREVRSFLEGLVLPFSGAASAQGVRFATVQYSDDPRTEFGLDALGSGGDVIRAIRELSYKGGNTRTGAAILHVADHVFLPQLARPGVPKVCILITDGKSQDLVDTAAQRLKGQGVKLFAVGIKNADPEELKRVASQPTSDFFFFVNDFSILRTLLPLVSRRVCTTAGGVPVTRPPDDSTSAPRDLVLSEPSSQSLRVQWTAASGPVTGYKVQYTPLTGLGQPLPSERQEVNVPAGETSVRLRGLRPLTEYQVTVIALYANSIGEAVSGTARTTALEGPELTIQNTTAHSLLVAWRSVPGATGYRVTWRVLSGGPTQQQELGPGQGSVLLRDLEPGTDYEVTVSTLFGRSVGPATSLMARTDASVEQTLRPVILGPTSILLSWNLVPEARGYRLEWRRETGLEPPQKVVLPSDVTRYQLDGLQPGTEYRLTLYTLLEGHEVATPATVVPTGPELPVSPVTDLQATELPGQRVRVSWSPVPGATQYRIIVRSTQGVERTLVLPGSQTAFDLDDVQAGLSYTVRVSARVGPREGSASVLTVRREPETPLAVPGLRVVVSDATRVRVAWGPVPGASGFRISWSTGSGPESSQTLPPDSTATDITGLQPGTTYQVAVSVLRGREEGPAAVIVARTDPLGPVRTVHVTQASSSSVTITWTRVPGATGYRVSWHSAHGPEKSQLVSGEATVAELDGLEPDTEYTVHVRAHVAGVDGPPASVVVRTAPEPVGRVSRLQILNASSDVLRITWVGVTGATAYRLAWGRSEGGPMRHQILPGNTDSAEIRGLEGGVSYSVRVTALVGDREGTPVSIVVTTPPEAPPALGTLHVVQRGEHSLRLRWEPVPRAQGFLLHWQPEGGQEQSRVLGPELSSYHLDGLEPATQYRVRLSVLGPAGEGPSAEVTARTESPRVPSIELRVVDTSIDSVTLAWTPVSRASSYILSWRPLRGPGQEVPGSPQTLPGISSSQRVTGLEPGVSYIFSLTPVLDGVRGPEASVTQTPVCPRGLADVVFLPHATQDNAHRAEATRRVLERLVLALGPLGPQAVQVGLLSYSHRPSPLFPLNGSHDLGIILQRIRDMPYMDPSGNNLGTAVVTAHRYMLAPDAPGRRQHVPGVMVLLVDEPLRGDIFSPIREAQASGLNVVMLGMAGADPEQLRRLAPGMDSVQTFFAVDDGPSLDQAVSGLATALCQASFTTQPRPEPCPVYCPKGQKGEPGEMGLRGQVGPPGDPGLPGRTGAPGPQGPPGSATAKGERGFPGADGRPGSPGRAGNPGTPGAPGLKGSPGLPGPRGDPGERGPRGPKGEPGAPGQVIGGEGPGLPGRKGDPGPSGPPGPRGPLGDPGPRGPPGLPGTAMKGDKGDRGERGPPGPGEGGIAPGEPGLPGLPGSPGPQGPVGPPGKKGEKGDSEDGAPGLPGQPGSPGEQGPRGPPGAIGPKGDRGFPGPLGEAGEKGERGPPGPAGSRGLPGVAGRPGAKGPEGPPGPTGRQGEKGEPGRPGDPAVVGPAVAGPKGEKGDVGPAGPRGATGVQGERGPPGLVLPGDPGPKGDPGDRGPIGLTGRAGPPGDSGPPGEKGDPGRPGPPGPVGPRGRDGEVGEKGDEGPPGDPGLPGKAGERGLRGAPGVRGPVGEKGDQGDPGEDGRNGSPGSSGPKGDRGEPGPPGPPGRLVDTGPGAREKGEPGDRGQEGPRGPKGDPGLPGAPGERGIEGFRGPPGPQGDPGVRGPAGEKGDRGPPGLDGRSGLDGKPGAAGPSGPNGAAGKAGDPGRDGLPGLRGEQGLPGPSGPPGLPGKPGEDGKPGLNGKNGEPGDPGEDGRKGEKGDSGASGREGRDGPKGERGAPGILGPQGPPGLPGPVGPPGQGFPGVPGGTGPKGDRGETGSKGEQGLPGERGLRGEPGSVPNVDRLLETAGIKASALREIVETWDESSGSFLPVPERRRGPKGDSGEQGPPGKEGPIGFPGERGLKGDRGDPGPQGPPGLALGERGPPGPSGLAGEPGKPGIPGLPGRAGGVGEAGRPGERGERGEKGERGEQGRDGPPGLPGTPGPPGPPGPKVSVDEPGPGLSGEQGPPGLKGAKGEPGSNGDQGPKGDRGVPGIKGDRGEPGPRGQDGNPGLPGERGMAGPEGKPGLQGPRGPPGPVGGHGDPGPPGAPGLAGPAGPQGPSGLKGEPGETGPPGRGLTGPTGAVGLPGPPGPSGLVGPQGSPGLPGQVGETGKPGAPGRDGASGKDGDRGSPGVPGSPGLPGPVGPKGEPGPTGAPGQAVVGLPGAKGEKGAPGGLAGDLVGEPGAKGDRGLPGPRGEKGEAGRAGEPGDPGEDGQKGAPGPKGFKGDPGVGVPGSPGPPGPPGVKGDLGLPGLPGAPGVVGFPGQTGPRGEMGQPGPSGERGLAGPPGREGIPGPLGPPGPPGSVGPPGASGLKGDKGDPGVGLPGPRGERGEPGIRGEDGRPGQEGPRGLTGPPGSRGERGEKGDVGSAGLKGDKGDSAVILGPPGPRGAKGDMGERGPRGLDGDKGPRGDNGDPGDKGSKGEPGDKGSAGLPGLRGLLGPQGQPGAAGIPGDPGSPGKDGVPGIRGEKGDVGFMGPRGLKGERGVKGACGLDGEKGDKGEAGPPGRPGLAGHKGEMGEPGVPGQSGAPGKEGLIGPKGDRGFDGQPGPKGDQGEKGERGTPGIGGFPGPSGNDGSAGPPGPPGSVGPRGPEGLQGQKGERGPPGERVVGAPGVPGAPGERGEQGRPGPAGPRGEKGEAALTEDDIRGFVRQEMSQHCACQGQFIASGSRPLPSYAADTAGSQLHAVPVLRVSHAEEEERVPPEDDEYSEYSEYSVEEYQDPEAPWDSDDPCSLPLDEGSCTAYTLRWYHRAVTGSTEACHPFVYGGCGGNANRFGTREACERRCPPRVVQSQGTGTAQD*
栄養障害型表皮水疱症の治療に用いるための組成物であって、VII型コラーゲンを産生するよう遺伝子改変された栄養障害型表皮水疱症患者の水疱由来細胞を含む、組成物。
[2]
水疱由来細胞が、COL7A1遺伝子を導入することにより遺伝子改変されている、前記1に記載の組成物。
[3]
水疱由来細胞のゲノムにCOL7A1遺伝子が導入されている、前記2に記載の組成物。
[4]
COL7A1遺伝子が、配列番号1の核酸配列と70%、80%、85%、90%、95%、96%、97%、98%または99%以上の配列同一性を有する核酸配列を含むか、配列番号2のアミノ酸配列と70%、80%、85%、90%、95%、96%、97%、98%または99%以上の配列同一性を有するアミノ酸配列をコードする核酸配列を含む、前記2または3に記載の組成物。
[5]
水疱由来細胞が、以下の1)~6)から選択される1つ以上の特徴を有するものである、前記1~4のいずれかに記載の組成物:
1)固相への接着性を有する、
2)CD73、CD105およびCD90からなる群より選択される一つ以上の表面マーカーが陽性である、
3)CD45、CD34、CD11b、CD79A、HLA-DRおよびCD31からなる群より選択される一つ以上の表面マーカーが陰性である、
4)骨芽細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い、
5)脂肪細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い、
6)軟骨細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い。
[6]
水疱由来細胞が、組成物に含まれる細胞で最も多い細胞である、前記1~5のいずれかに記載の組成物。
[7]
水疱由来細胞が、組成物に含まれる細胞の70%、80%、85%、90%、95%、96%、97%、98または99%以上を占める、前記1~6のいずれかに記載の組成物。
[8]
組成物が、実質的に水疱由来細胞以外の細胞を含まない、前記1~7のいずれかに記載の組成物。
[9]
患部に投与される、前記1~8のいずれかに記載の組成物。
[10]
水疱内に投与される、前記1~9のいずれかに記載の組成物。
[11]
ゲノム編集により水疱由来細胞が遺伝子改変されている、前記1~10のいずれかに記載の組成物。
[12]
ゲノム編集が、CRISPR/Cas9による、前記11に記載の組成物。
[13]
ウイルスベクターにより水疱由来細胞が遺伝子改変されている、前記1~10のいずれかに記載の組成物。
[14]
ウイルスベクターが、レトロウイルスベクターまたはレンチウイルスベクターである、前記13に記載の組成物。
[15]
ウイルスベクターが、レンチウイルスベクターである、前記13または14に記載の組成物。
栄養障害型表皮水疱症の治療に使用するための組成物の製造方法であって、
VII型コラーゲンを産生するよう栄養障害型表皮水疱症患者の水疱由来細胞を遺伝子改変すること、および
該遺伝子改変された水疱由来細胞を含む組成物を調製すること
を含む方法。
[17]
栄養障害型表皮水疱症を治療するための方法であって、VII型コラーゲンを産生するよう遺伝子改変された栄養障害型表皮水疱症患者の水疱由来細胞を含む組成物を前記患者に投与することを含む方法。
[18]
水疱由来細胞が、COL7A1遺伝子を導入することにより遺伝子改変されている、前記17に記載の方法。
[19]
水疱由来細胞のゲノムにCOL7A1遺伝子が導入されている、前記18に記載の方法。
[20]
COL7A1遺伝子が、配列番号1の核酸配列と70%、80%、85%、90%、95%、96%、97%、98%または99%以上の配列同一性を有する核酸配列を含むか、配列番号2のアミノ酸配列と70%、80%、85%、90%、95%、96%、97%、98%または99%以上の配列同一性を有するアミノ酸配列をコードする核酸配列を含む、前記18または19に記載の方法。
[21]
ゲノム編集により水疱由来細胞が遺伝子改変されている、前記17~20のいずれかに記載の方法。
[22]
ゲノム編集が、CRISPR/Cas9による、前記21に記載の方法。
[23]
ウイルスベクターにより水疱由来細胞が遺伝子改変されている、前記17~20のいずれかに記載の方法。
[24]
ウイルスベクターが、レトロウイルスベクターまたはレンチウイルスベクターである、前記23に記載の方法。
[25]
ウイルスベクターが、レンチウイルスベクターである、前記23または24に記載の方法。
[26]
患者への投与に先立ち、VII型コラーゲンを産生するよう水疱由来細胞を遺伝子改変することをさらに含む、前記17~25のいずれかに記載の方法。
[27]
COL7A1遺伝子を導入することにより水疱由来細胞を遺伝子改変する、前記16または26に記載の方法。
[28]
水疱由来細胞のゲノムにCOL7A1遺伝子を導入する、前記27に記載の方法。
[29]
COL7A1遺伝子が、配列番号1の核酸配列と70%、80%、85%、90%、95%、96%、97%、98%または99%以上の配列同一性を有する核酸配列を含むか、配列番号2のアミノ酸配列と70%、80%、85%、90%、95%、96%、97%、98%または99%以上の配列同一性を有するアミノ酸配列をコードする核酸配列を含む、前記27または28に記載の方法。
[30]
ゲノム編集により水疱由来細胞を遺伝子改変する、前記16および26~29のいずれかに記載の方法。
[31]
ゲノム編集が、CRISPR/Cas9による、前記30に記載の方法。
[32]
ウイルスベクターにより水疱由来細胞を遺伝子改変する、前記16および26~29のいずれかに記載の方法。
[33]
ウイルスベクターが、レトロウイルスベクターまたはレンチウイルスベクターである、前記32に記載の方法。
[34]
ウイルスベクターが、レンチウイルスベクターである、前記32または33に記載の方法。
[35]
遺伝子改変に先立ち、栄養障害型表皮水疱症患者の水疱から細胞を得ることをさらに含む、前記16および26~34のいずれかに記載の方法。
[36]
水疱由来細胞が、組成物に含まれる細胞で最も多い細胞である、前記16~35のいずれかに記載の方法。
[37]
水疱由来細胞が、組成物に含まれる細胞の70%、80%、85%、90%、95%、96%、97%、98または99%以上を占める、前記16~36のいずれかに記載の方法。
[38]
組成物が、実質的に水疱由来細胞以外の細胞を含まない、前記16~37のいずれかに記載の方法。
[39]
組成物が、患部に投与される、前記17~38のいずれかに記載の方法。
[40]
組成物が、水疱内に投与される、前記17~39のいずれかに記載の方法。
栄養障害型表皮水疱症を治療するための医薬の製造のための、VII型コラーゲンを産生するよう遺伝子改変された栄養障害型表皮水疱症患者の水疱由来細胞を含む組成物の使用。
[42]
組成物が水疱内に投与されるものである、前記41に記載の使用。
栄養障害型表皮水疱症を治療するための、VII型コラーゲンを産生するよう遺伝子改変された栄養障害型表皮水疱症患者の水疱由来細胞を含む組成物の使用。
[44]
組成物が水疱内に投与されるものである、前記43に記載の使用。
栄養障害型表皮水疱症の治療における使用のための、VII型コラーゲンを産生するよう遺伝子改変された栄養障害型表皮水疱症患者の水疱由来細胞。
[46]
水疱内に投与されるものである、前記45に記載の細胞。
配列番号3~5のいずれかの配列またはこれに相補的な配列を含む、gRNA。
[48]
前記47のgRNAをコードする核酸配列を含むベクター。
栄養障害型表皮水疱症患者の水疱内容物を固相上で培養する工程を含む、細胞の製造方法。
[50]
前記49に記載の方法によって製造される細胞。
[51]
以下の1)~6)から選択される1つ以上の特徴を有する、前記50に記載の細胞:
1)固相への接着性を有する、
2)CD73、CD105およびCD90からなる群より選択される一つ以上の表面マーカーが陽性である、
3)CD45、CD34、CD11b、CD79A、HLA-DRおよびCD31からなる群より選択される一つ以上の表面マーカーが陰性である、
4)骨芽細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い、
5)脂肪細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い、
6)軟骨細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い。
以下の工程を含む、細胞の製造方法:
1)栄養障害型表皮水疱症患者の水疱内容物を固相上で培養する工程、
2)培養工程1)によって得られた細胞を、VII型コラーゲンを産生するよう遺伝子改変する工程。
[53]
前記52に記載の方法によって製造される細胞。
[54]
VII型コラーゲンを産生するよう遺伝子改変された、栄養障害型表皮水疱症患者の水疱由来細胞。
[55]
COL7A1遺伝子を導入することにより遺伝子改変されている、前記53または54に記載の細胞。
[56]
細胞のゲノムにCOL7A1遺伝子が導入されている、前記55に記載の細胞。
[57]
COL7A1遺伝子が、配列番号1の核酸配列と70%、80%、85%、90%、95%、96%、97%、98%または99%以上の配列同一性を有する核酸配列を含むか、配列番号2のアミノ酸配列と70%、80%、85%、90%、95%、96%、97%、98%または99%以上の配列同一性を有するアミノ酸配列をコードする核酸配列を含む、前記56に記載の細胞。
[58]
ゲノム編集により遺伝子改変されている、前記53~57のいずれかに記載の細胞。
[59]
ゲノム編集が、CRISPR/Cas9による、前記58に記載の細胞。
[60]
ウイルスベクターにより遺伝子改変されている、前記53~57のいずれかに記載の細胞。
[61]
ウイルスベクターが、レトロウイルスベクターまたはレンチウイルスベクターである、前記60に記載の細胞。
[62]
ウイルスベクターが、レンチウイルスベクターである、前記60または61に記載の細胞。
[63]
以下の1)~6)から選択される1つ以上の特徴を有する、前記53~62のいずれかに記載の細胞:
1)固相への接着性を有する、
2)CD73、CD105およびCD90からなる群より選択される一つ以上の表面マーカーが陽性である、
3)CD45、CD34、CD11b、CD79A、HLA-DRおよびCD31からなる群より選択される一つ以上の表面マーカーが陰性である、
4)骨芽細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い、
5)脂肪細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い、
6)軟骨細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い。
栄養障害型表皮水疱症患者の水疱内容液を採取し、300gで 5分遠心した。得られた沈殿を培地(Mesenchymal Stem Cell Growth Medium 2 (PromoCell社、C-28009)にペニシリンおよびストレプトマイシンをそれぞれ終濃度100unit/mLおよび100μg/mLとなるよう添加したもの)で懸濁してコラーゲンIコート 6-well plateに播種し、37℃、5%CO2で培養することにより、付着性の細胞を得た。その後、適宜培地交換と継代を行って所望の細胞数まで増殖させた(培養開始20日後までの培養経過を図1に示す)。かかる方法によって得た細胞を、以下において「水疱由来細胞」とも称する。下記表面マーカー解析と分化誘導の実験には3継代目の細胞、遺伝子導入には3~4継代目の細胞をそれぞれ用いた。また、上記の培地に代えてMesenchymal Stem Cell Growth Medium 2 (PromoCell社、C-28009)とMSCGM Mesenchymal Stem Cell Growth Medium(Lonza社、PT-3001)の等量混合培地や、Cellartis MSC Xeno-Free Culture Medium (タカラバイオ社、Y50200)を用いた場合でも同等の水疱由来細胞が得られることを確認した。
a) 表面マーカー解析(FACS)
上記1.で得られた水疱由来細胞と、ヒト骨髄由来間葉系幹細胞(以下、BM-MSCとも称する)[PromoCell社 (Heidelberg, Germany) または Lonza社 (Basel, Switzerland)より購入]について、以下の手順で表面マーカー解析を行った: 細胞をAccutase-Solution (PromoCell社、C-41310)を用いてプレートから剥がし、培地で洗浄した後、細胞数の計測結果を基に、2本のチューブに細胞を10万個ずつ分取した。細胞をFlow Cytometry Staining Buffer (1X) (R&D Systems社、FC001)で1回洗浄し、100μlのFlow Cytometry Staining Buffer (1X)に再懸濁した。Fc受容体のブロッキングを行うため、Human TruStain FcXTM (BioLegend社、422301)を5μl加えて、氷上で10分間反応させた。1本のチューブには、Human Mesenchymal Stem Cell Verification Flow Kit (R&D Systems社、FMC020)に含まれるCD73-CFS Mouse IgG2B、CD90-APC Mouse IgG2A、およびNegative Marker Cocktail(CD45-PE Mouse IgG1、CD34-PE Mouse IgG1、CD11b-PE Mouse IgG2B、CD79A-PE Mouse IgG1、HLA-DR-PE Mouse IgG1)をそれぞれ10μlずつ加え、さらにBrilliant Violet 421TM anti-human CD105 Antibody (BioLegend社、323219)を5μl加えて、室温・遮光下で30分間反応させた。もう1本のチューブは陰性コントロールとして使用するため、それぞれのアイソタイプコントロール抗体を同量加えて、室温・遮光下で30分間反応させた。細胞を2mlのFlow Cytometry Staining Buffer (1X)で1回洗浄し、300μlのFlow Cytometry Staining Buffer (1X)に再懸濁した後、BD FACSAria(BD社)で解析した。また、CD31についても以下の手順でFACS解析を行い、水疱由来細胞およびヒトBM-MSCにおける発現有無を確認した:細胞をAccutase-Solution (PromoCell社、C-41310)を用いてプレートから剥がし、培地で洗浄した後、細胞数の計測結果を基に、2本のチューブに細胞を10万個ずつ分取した。細胞を2%FBS含有PBSで洗浄し、100μlの2%FBS含有PBSに再懸濁した。Fc受容体のブロッキングを行うため、Human TruStain FcXTM (BioLegend社, 422301)を5μl加えて、氷上で10分間反応させた。1本のチューブには、APC anti-human CD31 Antibody (BioLegend社, 303116)を5μl(タンパク質量0.4μg)加えて、氷上・遮光下で60分間反応させた。もう1本のチューブは陰性コントロールとして使用するため、APC Mouse IgG1, κ Isotype Ctrl Antibody (BioLegend社, 400120)を2μl(タンパク質量0.4μg)加えて、氷上・遮光下で60分間反応させた。細胞を2mlの2%FBS含有PBSで1回洗浄した後、300μlの2%FBS含有PBSに再懸濁し、BD FACSAria(BD社)で解析した。
上記1.で得られた水疱由来細胞とBM-MSCについて、下記の条件で骨芽細胞、脂肪細胞および軟骨細胞への分化誘導を行った。
骨芽細胞への分化誘導:
細胞を、0.1μM Dexamethasone、0.2mM Ascorbic acid 2-phosphate、10mM Glycerol 2-phosphate(数値はいずれも終濃度)を含む培地で、37℃、5%CO2の条件下、3週間培養(週2回培地交換)して骨芽細胞への分化を誘導した。TRACP & ALP Assay Kit (タカラバイオ社, MK301)を製品マニュアル通りに用いて、アルカリホスファターゼ(ALP)染色を行った。
脂肪細胞への分化誘導:
細胞を、1μM Dexamethasone、0.5mM 3-Isobutyl-1-methylanxthine (IBMX)、10μg/mL Insulin、100μM Indomethacin(数値はいずれも終濃度)を含む培地で、37℃、5%CO2の条件下、3週間培養(週2回培地交換)して脂肪細胞への分化を誘導した。リピットアッセイキット(コスモ・バイオ社、AK09F)を製品マニュアル通りに用いて、細胞のオイルレッドO染色を行った。
軟骨細胞への分化誘導:
Human Mesenchymal Stem Cell (hMSC) Chondrogenic Differentiation Medium Bullet Kit(tm) (Lonza社, PT-3003)の構成品を指示通りに混合して、軟骨分化誘導培地(不完全培地)を調製した。これにRecombinant Human TGF-beta 3 Protein (R&D Systems社, 243-B3)を、最終濃度10ng/mlになるように添加して、軟骨分化誘導培地(完全培地)を使用毎に調製した。第三継代細胞をAccutase-Solution PromoCell社, C-41310)で剥がし、培地で洗浄した後、細胞数の計測結果を基に、250,000個の細胞を15mlポリプロピレンコニカルチューブに分取した。細胞を軟骨分化誘導培地(不完全培地)で2回洗浄し、上清を除去した後、500μlの軟骨分化誘導培地(完全培地)で懸濁した。150gで5分間遠心して細胞のペレットを形成させ、ふたを緩めてCO2インキュベーターに静置し(37℃、5%CO2)、その後2~3日毎に培地(完全培地)を交換した。3週間経過後にペレットを取り出して4%パラホルムアルデヒドで固定し、凍結切片を作成してアルシアンブルー染色により軟骨細胞由来のプロテオグリカンを染色した。ポジティブコントロールとしてヒト骨髄由来間葉系幹細胞についても同様の分化誘導操作を行った。
ヒトゲノム内のAAVS1(Adeno-associated virus integration site 1)領域においてCRISPR-Cas9システムによる切断効率が良好な位置を選択するため、3種類のsgRNAを作製した。AAVS1領域は、遺伝子導入による影響を受けにくい安全領域(セーフ・ハーバー/safe harbor)である。CRISPR-Cas9システムは「NGG」の塩基配列を認識し、その3塩基上流を切断することから、末端に「GG」が配置される領域を選択し、「NGG」の上流20塩基の標的配列を含むsgRNA(sgAAVS1-#1~#3)を設計した(図4、上;表1)。
AAVS1領域へのCOL7A1遺伝子の導入のため、CAGプロモーターの制御下にCOL7A1遺伝子を発現するプラスミドを設計した(図5)。COL7A1 cDNAは、Flexi ORF sequence-verified clone (Promega, Madison, WI, USA)より得た。COL7A1 cDNAをpENTR1Aプラスミド(Thermo Fisher Scientific, A10462)にサブクローニングし、pENTR1A-COL7A1を得た。LRリコンビナーゼ (Thermo Fisher Scientific) を用いたGateway反応によってpENTR1A-COL7A1からpAAVS1-P-CAG-DEST (Addgene plasmid # 80490)へCOL7A1 cDNAを導入し、ドナープラスミドpAAVS1-P-CAG-COL7A1を得た。
水疱形成を示すCol7A1遺伝子ノックアウトマウス(Col7a1-/-)の新生児の全層皮膚を切除し、免疫不全マウス(NOD-SCID)の背部に移植した。移植直後に皮膚表面をつまみ、かつ擦ることで水疱を形成させ、直ちに表皮下の空間(水疱内)に上記4.で作成した1.0×106個の遺伝子改変水疱由来細胞を注入し(図6)、フィイルムドレッシング材で密封した(対照群のマウスには、遺伝子改変していない水疱由来細胞を1.0×106個注入した)。4週間後に皮膚を採取し、抗VII型コラーゲン抗体(clone LH7.2; Sigma Aldrich, C6805)を用いた免疫染色により、VII型コラーゲン基底膜への沈着を確認した。その結果、遺伝子改変水疱由来細胞を水疱内に注入したマウスの基底膜近傍にVII型コラーゲンの沈着が認められた(図7)。
Claims (15)
- 栄養障害型表皮水疱症の治療に用いるための組成物であって、VII型コラーゲンを産生するよう遺伝子改変された栄養障害型表皮水疱症患者の水疱由来細胞を含む、組成物。
- 水疱由来細胞が、COL7A1遺伝子を導入することにより遺伝子改変されている、請求項1に記載の組成物。
- COL7A1遺伝子が、配列番号1の核酸配列と90%以上の配列同一性を有する核酸配列を含むか、配列番号2のアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列をコードする核酸配列を含む、請求項2に記載の組成物。
- 水疱由来細胞が、以下の1)~6)から選択される1つ以上の特徴を有するものである、請求項1~3のいずれかに記載の組成物:
1)固相への接着性を有する、
2)CD73、CD105およびCD90からなる群より選択される一つ以上の表面マーカーが陽性である、
3)CD45、CD34、CD11b、CD79A、HLA-DRおよびCD31からなる群より選択される一つ以上の表面マーカーが陰性である、
4)骨芽細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い、
5)脂肪細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い、
6)軟骨細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い。 - 水疱由来細胞が、組成物に含まれる細胞で最も多い細胞である、請求項1~4のいずれかに記載の組成物。
- 水疱内に投与される、請求項1~5のいずれかに記載の組成物。
- 栄養障害型表皮水疱症患者の水疱内容物を固相上で培養する工程を含む、細胞の製造方法。
- 請求項7に記載の方法によって製造される細胞。
- 以下の1)~6)から選択される1つ以上の特徴を有する、請求項8に記載の細胞:
1)固相への接着性を有する、
2)CD73、CD105およびCD90からなる群より選択される一つ以上の表面マーカーが陽性である、
3)CD45、CD34、CD11b、CD79A、HLA-DRおよびCD31からなる群より選択される一つ以上の表面マーカーが陰性である、
4)骨芽細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い、
5)脂肪細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い、
6)軟骨細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い。 - 以下の工程を含む、細胞の製造方法:
1)栄養障害型表皮水疱症患者の水疱内容物を固相上で培養する工程、
2)培養工程1)によって得られた細胞を、VII型コラーゲンを産生するよう遺伝子改変する工程。 - 請求項10に記載の方法によって製造される細胞。
- VII型コラーゲンを産生するよう遺伝子改変された、栄養障害型表皮水疱症患者の水疱由来細胞。
- COL7A1遺伝子を導入することにより遺伝子改変されている、請求項11または12に記載の細胞。
- COL7A1遺伝子が、配列番号1の核酸配列と90%以上の配列同一性を有する核酸配列を含むか、配列番号2のアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列をコードする核酸配列を含む、請求項13に記載の細胞。
- 以下の1)~6)から選択される1つ以上の特徴を有する、請求項11~14のいずれかに記載の細胞:
1)固相への接着性を有する、
2)CD73、CD105およびCD90からなる群より選択される一つ以上の表面マーカーが陽性である、
3)CD45、CD34、CD11b、CD79A、HLA-DRおよびCD31からなる群より選択される一つ以上の表面マーカーが陰性である、
4)骨芽細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い、
5)脂肪細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い、
6)軟骨細胞への分化能を有しない、又は骨髄由来間葉系幹細胞と比較して当該分化能が低い。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020237005854A KR20230043906A (ko) | 2020-07-22 | 2020-11-26 | 영양 장애형 표피 수포증의 치료약 |
AU2020459825A AU2020459825A1 (en) | 2020-07-22 | 2020-11-26 | Therapeutic agent for dystrophic epidermolysis bullosa |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020125620 | 2020-07-22 | ||
JP2020-125620 | 2020-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022018884A1 true WO2022018884A1 (ja) | 2022-01-27 |
Family
ID=79729198
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/044096 WO2022018884A1 (ja) | 2020-07-22 | 2020-11-26 | 栄養障害型表皮水疱症の治療薬 |
PCT/JP2021/027279 WO2022019325A1 (ja) | 2020-07-22 | 2021-07-21 | 栄養障害型表皮水疱症の治療薬 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/027279 WO2022019325A1 (ja) | 2020-07-22 | 2021-07-21 | 栄養障害型表皮水疱症の治療薬 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240050481A1 (ja) |
JP (1) | JPWO2022019325A1 (ja) |
KR (1) | KR20230043906A (ja) |
AU (1) | AU2020459825A1 (ja) |
WO (2) | WO2022018884A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023140349A1 (ja) * | 2022-01-21 | 2023-07-27 | 国立大学法人大阪大学 | 細胞シート |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018235834A1 (ja) * | 2017-06-19 | 2018-12-27 | 国立大学法人北海道大学 | 表皮水疱症の治療剤 |
JP2019506925A (ja) * | 2016-01-04 | 2019-03-14 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 遺伝子修正自己ケラチノサイトを使用する劣性栄養障害型表皮水疱症のための遺伝子療法 |
WO2019060719A1 (en) * | 2017-09-22 | 2019-03-28 | University Of Miami | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BULLETIN EPIDERMOLYSIS |
JP2019508454A (ja) * | 2016-03-18 | 2019-03-28 | イントレキソン コーポレーション | Vii型コラーゲン欠損症の治療のための組成物及び方法 |
JP2019142819A (ja) * | 2018-02-22 | 2019-08-29 | 学校法人順天堂 | 栄養障害型表皮水疱症治療剤 |
WO2020149395A1 (ja) * | 2019-01-18 | 2020-07-23 | 国立大学法人大阪大学 | 栄養障害型表皮水疱症治療薬 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3585897A1 (en) | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders |
-
2020
- 2020-11-26 WO PCT/JP2020/044096 patent/WO2022018884A1/ja active Application Filing
- 2020-11-26 KR KR1020237005854A patent/KR20230043906A/ko unknown
- 2020-11-26 AU AU2020459825A patent/AU2020459825A1/en active Pending
-
2021
- 2021-07-21 JP JP2022538037A patent/JPWO2022019325A1/ja active Pending
- 2021-07-21 WO PCT/JP2021/027279 patent/WO2022019325A1/ja active Application Filing
- 2021-07-21 US US18/017,149 patent/US20240050481A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019506925A (ja) * | 2016-01-04 | 2019-03-14 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 遺伝子修正自己ケラチノサイトを使用する劣性栄養障害型表皮水疱症のための遺伝子療法 |
JP2019508454A (ja) * | 2016-03-18 | 2019-03-28 | イントレキソン コーポレーション | Vii型コラーゲン欠損症の治療のための組成物及び方法 |
WO2018235834A1 (ja) * | 2017-06-19 | 2018-12-27 | 国立大学法人北海道大学 | 表皮水疱症の治療剤 |
WO2019060719A1 (en) * | 2017-09-22 | 2019-03-28 | University Of Miami | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BULLETIN EPIDERMOLYSIS |
JP2019142819A (ja) * | 2018-02-22 | 2019-08-29 | 学校法人順天堂 | 栄養障害型表皮水疱症治療剤 |
WO2020149395A1 (ja) * | 2019-01-18 | 2020-07-23 | 国立大学法人大阪大学 | 栄養障害型表皮水疱症治療薬 |
Non-Patent Citations (1)
Title |
---|
ITOH M. ET AL.: "Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 98, April 2020 (2020-04-01), pages 163 - 172, XP086202397, DOI: 10.1016/j.jdermsci.2020.04.004 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023140349A1 (ja) * | 2022-01-21 | 2023-07-27 | 国立大学法人大阪大学 | 細胞シート |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022019325A1 (ja) | 2022-01-27 |
WO2022019325A1 (ja) | 2022-01-27 |
US20240050481A1 (en) | 2024-02-15 |
AU2020459825A1 (en) | 2023-03-16 |
KR20230043906A (ko) | 2023-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2744603C2 (ru) | Композиции, повышающие число копий вектора (чкв), и способы их применения | |
JP7263327B2 (ja) | 細胞の遺伝子修飾のための非組込みdnaベクター | |
CN105612176B (zh) | Hla g修饰的细胞及方法 | |
AU2016278959A1 (en) | CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage | |
AU2011377617B2 (en) | Improved gene therapy methods | |
KR20160075676A (ko) | 방법 | |
JP2019517281A (ja) | 神経セロイドリポフスチン症の遺伝子治療 | |
WO2020149395A1 (ja) | 栄養障害型表皮水疱症治療薬 | |
EP3413896B1 (en) | Vcn enhancer compositions and methods of using the same | |
WO2022018884A1 (ja) | 栄養障害型表皮水疱症の治療薬 | |
EP3600448A1 (en) | Vectors and compositions for treating hemoglobinopathies | |
US20190284533A1 (en) | Vcn enhancer compositions and methods of using the same | |
JP2022512674A (ja) | 人工トランス活性化因子による選択 | |
WO2023140349A1 (ja) | 細胞シート | |
US20190099451A1 (en) | Retroviral construct harboring a let-7 insensitive nucleic acid encoding hmga2 and methods of use thereof | |
JP2020500562A (ja) | ムコ多糖症ii型のための遺伝子治療 | |
KR20230131816A (ko) | 저면역원성 줄기세포, 줄기세포로부터 분화되거나 유래된 저면역원성 세포및 이의 제조방법 | |
WO2024003607A1 (en) | Constructs, compositions, cells and methods for cell therapy | |
KR20220017927A (ko) | 영양요구 조절가능 세포를 사용한 방법 및 조성물 | |
CN113544279A (zh) | 包含芳基硫酸酯酶a的重组载体及其在用于治疗异染性脑白质营养不良的干细胞治疗中的用途 | |
Geisler et al. | ESGCT, DGGT, GSZ, and ISCT 2009 Oral Presentations | |
Cathomen et al. | XVIII Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) October 22–25, 2010 Milan, Italy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20946372 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20237005854 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020459825 Country of ref document: AU Date of ref document: 20201126 Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20946372 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |